Suven Life Sciences Ltd

Suven Life Sciences Ltd recorded a robust intraday rally on 3 Feb 2026, surging to an intraday high of Rs 149.2, marking an 8.39% increase from its previous close. The stock outperformed its sector and the broader market, reflecting strong trading momentum throughout the session.

Suven Life Sciences Ltd witnessed a robust start to the trading session on 3 Feb 2026, opening with a notable gap up of 5.34%, reflecting positive market sentiment within the Healthcare Services sector. The stock’s intraday performance demonstrated sustained momentum, outperforming both its sector peers and the broader Sensex index.

Suven Life Sciences Ltd (NSE: 588414) is currently navigating a complex technical landscape as recent momentum indicators reveal a shift from bearish to mildly bearish trends. Despite a strong long-term return profile, the stock’s near-term technical parameters suggest caution for investors amid mixed signals from MACD, RSI, and moving averages.

Suven Life Sciences Ltd demonstrated robust intraday performance on 1 Feb 2026, surging 7.3% to touch a day’s high of Rs 141.9, significantly outperforming the broader Sensex which gained a modest 0.08% during the session.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 August 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 February 2026, providing investors with the latest insights into its performance and prospects.

Suven Life Sciences Ltd., a Hyderabad-based healthcare services company, reported catastrophic losses in Q3 FY26, with net profit plunging to a staggering ₹101.92 crores loss—its worst quarterly performance on record. The devastating results, marking a 50.06% sequential deterioration from Q2 FY26's ₹77.31 crores loss, have sent the stock into a prolonged bearish spiral, with shares trading at ₹130.80 as of January 29, 2026, down 56.83% from their 52-week high of ₹303.00.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 January 2026, providing investors with the latest insights into its performance and outlook.

Suven Life Sciences Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend across multiple timeframes. The stock’s recent performance, combined with deteriorating moving averages and momentum oscillators, suggests increased selling pressure despite its strong long-term returns relative to the Sensex.

Suven Life Sciences Ltd has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. Despite a recent uptick in price, the stock remains under pressure with a strong sell rating, underscoring cautious investor sentiment in the healthcare services sector.

Suven Life Sciences Ltd, a key player in the Healthcare Services sector, has experienced a subtle shift in its technical momentum as it transitions from a bearish to a mildly bearish trend. Despite a recent downgrade in its Mojo Grade to Strong Sell, the stock’s long-term returns remain robust, though near-term indicators suggest caution for investors.

Suven Life Sciences Ltd, a key player in the Healthcare Services sector, has recently experienced a shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite a strong year-to-date return of 27.67%, the stock’s technical indicators suggest caution as bearish signals dominate daily and weekly charts, reflecting growing selling pressure and potential downside risks.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Suven Life Sciences, a key player in the Healthcare Services sector, is exhibiting a nuanced shift in its technical momentum as recent evaluation adjustments reflect a transition from a bearish to a mildly bearish trend. This development is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and other momentum oscillators, signalling a period of consolidation and cautious investor sentiment.

Suven Life Scie., a small-cap player in the Healthcare Services sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and operational performance. Recent evaluation metrics indicate a more cautious outlook driven by persistent losses and valuation concerns, despite some short-term stock price gains.

Suven Life Sciences, a key player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. Recent market data reveals a nuanced picture of price movement and indicator behaviour, underscoring the importance of a detailed technical analysis for investors tracking this stock.

Suven Life Sciences, a key player in the Healthcare Services sector, has exhibited notable shifts in its technical momentum, reflecting a complex interplay of indicator signals. Recent market data reveals a nuanced picture of price movement and momentum, with mixed signals from MACD, RSI, moving averages, and other technical parameters shaping investor sentiment.